Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM
Status:
Unknown status
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
1. Primary Objective To assess the response rate of sequential VAD (Vincristine,
Adriamycin, Dexamethasone) and VTD (Velcade, Thalidomide, Dexamethasone) induction
therapy as a first line treatment for the patients with multiple myeloma
2. Secondary Objectives
1. To assess the progression free survival, duration of response, and overall survival
of patients given sequential VAD and VTD induction followed by high dose therapy
with autologous stem cell transplantation and maintenance treatment with Velcade
2. To assess the toxicities of sequential VAD and VTD induction chemotherapy, high
dose therapy with autologous stem cell transplantation, and of maintenance
treatment with Velcade.